Stock market today: S&P 500 extends monthly win streak despite Nvidia-led stumble
NanoVibronix , Inc. (NASDAQ:NAOV), a micro-cap medical device company with a market capitalization of $2.46 million, announced Friday that its Special Meeting of Stockholders was opened and immediately adjourned without conducting any business because a quorum was not present. According to InvestingPro analysis, the company’s stock has experienced significant volatility, declining over 89% in the past year. The meeting will be reconvened virtually on Thursday, July 17, 2025, at 10:00 a.m. Eastern Time. The company stated that the record date for shareholders eligible to vote remains May 16, 2025. With the company’s current ratio at 0.47 and rapidly depleting cash reserves, as highlighted by InvestingPro’s analysis, this meeting holds particular significance for stakeholders.
According to the press release statement, the new deadline for submitting proxies for the reconvened meeting is 11:59 p.m. Eastern Time on July 16, 2025, for shareholders holding shares directly. Proxies already submitted will remain valid for the upcoming meeting. Shareholders who have not yet voted can do so prior to the new deadline or online at the reconvened meeting. Those who have already submitted voting instructions do not need to take further action unless they wish to change or revoke their vote.
NanoVibronix also noted that it previously filed a Definitive Proxy Statement with the Securities and Exchange Commission (SEC) on June 20, 2025, and mailed it to shareholders of record as of the record date. The company’s directors and executive officers may be considered participants in the solicitation of proxies for the meeting, as described in the proxy materials and the company’s annual report.
The information in this article is based on a statement released in the company’s SEC filing.
In other recent news, NanoVibronix, Inc. announced a correction to its Series G Preferred Stock designation, adjusting the floor price from $1.02 to $1.91, as filed with the Delaware Secretary of State. Additionally, the company has been granted a U.S. patent for its pediatric feeding tube guidance system, which presents a significant market opportunity. Following its acquisition of ENvue Medical (TASE:BLWV) Holdings, NanoVibronix appointed Doron Besser as the new CEO, succeeding Brian Murphy. The company also clarified that it is not proceeding with a $26 million stock offering, refuting claims made by unauthorized sources. Meanwhile, NanoVibronix has set terms for a $10 million public offering, involving Series G Convertible Preferred Stock and Warrants. Dawson James Securities, Inc. is managing this offering, which aims to redeem outstanding debentures and notes, with additional funds allocated for corporate purposes. These developments reflect NanoVibronix’s ongoing efforts to strengthen its market position and financial standing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.